---
title: "SPDB Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)"
description: "In a report released yesterday, from SPDB maintained a Buy rating on Zai Lab Ltd, with a price target of HK$20.00. The company’s shares closed last Friday at HK$12.44.Claim 50% Off TipRanks PremiumUnl"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274601457.md"
published_at: "2026-02-03T05:06:16.000Z"
---

# SPDB Reaffirms Their Buy Rating on Zai Lab Ltd (1ZLB)

> In a report released yesterday, from SPDB maintained a Buy rating on Zai Lab Ltd, with a price target of HK$20.00. The company’s shares closed last Friday at HK$12.44.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential Zai Lab Ltd has an analyst consensus of Strong Buy, with a price target consensus of €3.21.

In a report released yesterday, from SPDB maintained a Buy rating on Zai Lab Ltd, with a price target of HK$20.00. The company’s shares closed last Friday at HK$12.44.

### Claim 50% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Zai Lab Ltd has an analyst consensus of Strong Buy, with a price target consensus of €3.21.

### Related Stocks

- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [09688.HK - ZAI LAB](https://longbridge.com/en/quote/09688.HK.md)
- [XBI.US - SPDR S&P Biotech](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [ZLAB.US - Zai Lab](https://longbridge.com/en/quote/ZLAB.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US - Invesco Biotechnology & Genome ETF](https://longbridge.com/en/quote/PBE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX | NEOS Investment Management LLC has reduced its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) by 61.6% in Q3, no | [Link](https://longbridge.com/en/news/276532688.md) |
| BUZZ-Vir Biotech slips after unveiling $200 mln stock offering plans | Vir Biotechnology's shares fell 5.2% to $9 in post-market trading following the announcement of a $200 million stock off | [Link](https://longbridge.com/en/news/276789230.md) |
| Protara Therapeutics Highlights Phase 2 TARA-002 Data in NMIBC, Cites Strong Response Rates at ASCO GU | Protara Therapeutics (NASDAQ:TARA) presented updated interim data from its Phase 2 ADVANCED-2 trial for TARA-002 in high | [Link](https://longbridge.com/en/news/276853821.md) |
| Edesa Biotech Reports Additional Results From Phase 3 Paridiprubart Study | Feb 24 (Reuters) - Edesa Biotech Inc:EDESA BIOTECH REPORTS ADDITIONAL POSITIVE RESULTS FROM PHASE 3 PARIDIPRUBART STUDYE | [Link](https://longbridge.com/en/news/276748950.md) |
| Beam Therapeutics tops Q4 profit estimates, signs financing deal | Beam Therapeutics reported Q4 earnings that exceeded analyst expectations, with EPS at $2.33 and net income of $244.3 mi | [Link](https://longbridge.com/en/news/276730924.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.